Immunovant Share Prices Plummet Amid Study Delays
Thursday, 30 May 2024, 16:07
Immunovant Share Prices Decline
The recent delays in studies have caused a significant impact on Immunovant's share prices, leading to a target cut by analysts. The uncertainties surrounding the study progress have raised concerns among investors, resulting in a decline in share prices.
Target Cut Amid Study Delays
With the study delays affecting the company's performance, investors are closely monitoring the situation for further developments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.